Skip to main content

Advertisement

Log in

Combination chemotherapy for ovarian cancer-lessons not yet learned?

  • Invited Commentary
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Thigpen JT: Chemotherapy for advanced ovarian cancer: overview of randomized trials. Semin Oncol 2000, 27:11–16.

    PubMed  CAS  Google Scholar 

  2. Muggia FM, Brady PS, Brady MF, et al.: Phase III randomized trial of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with advanced ovarian cancer: a GOG study. J Clin Oncol 2000, 18:106–115.

    PubMed  CAS  Google Scholar 

  3. Colombo N, on behalf of ICON collaborators: Randomized trial of paclitaxel and carboplatin versus a control arm of carboplatin or CAP (ICON 3) [abstract]. Proc ASCO 2000, 19:379a.

    Google Scholar 

  4. Finkler N, Gordon A, Crozier M, et al.: Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian cancer [abstract]. Proc ASCO 2001, 20:208a.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaye, S.B. Combination chemotherapy for ovarian cancer-lessons not yet learned?. Curr Oncol Rep 4, 185–186 (2002). https://doi.org/10.1007/s11912-002-0013-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-002-0013-3

Keywords

Navigation